CAR-T细胞 z-bo 2020-09-30 350

　　New research shows that adult lymphoma patients treated with chimeric antigen receptor (CAR) T cells (CAR-T) have shown significant improvement in various self-reported quality of life indicators. it has been. This provides evidence that CAR-T cells can not only extend the survival period of cancer patients, but also improve the quality of life after treatment. Before the advent of CAR-T cell therapy and other forms of cellular immunotherapy, patients with diffuse large cell B-cell lymphoma (DLBCL) had limited treatment options, and patients with advanced DLBCL usually ran out of existing treatment options. The development process of CAR-T cell therapy involves collecting the patient’s own T cells, genetically modifying them to target specific proteins on the surface of cancer cells, and then re-creating these genetically modified T cells in the same patient. It is injection. Kill cancer cells. CAR-T cells are expected to treat DLBCL patients and show sustained clinical remission and better survival rates.

　　In order to determine the other benefits of CAR-T cells for patients, the researchers participating in this new study live in relapsed/refractory DLBCL adult patients receiving CAR-T treatment called tisagen lecleucel. The quality of the evaluation. These patients were asked to use two tools to report their quality of life. One is a tool to assess physical, social, emotional, functional health and symptoms related to disease and treatment, and the other is a tool to induce perceptions related to physical, social function and health. Yes. Reactions related to mental health. Unless the patient stops participating in the study or the patient's condition deteriorates, collect data before treatment and recollect data at 3, 6, 12, and 18 months after treatment. Of the 108 patients who were evaluated, 57 patients received triphenyltriazide treatment with complete or partial remission. The baseline scores for the quality of life results reported by patients are similar between the entire patient population and those who respond to treatment, but over time, the quality of life for patients remains at a high level. Shows improvements. Compared to baseline, patients who responded to treatment experienced the most significant improvements in overall health, vitality, physical function, and social function.

　　The paper’s co-author, Dr. Richard Majiartz of Oregon Health Sciences University School of Medicine, said: “Many patients in the advanced stages of the disease feel depressed and self-isolated, but in this study, patients continue to improve their functional status and their interaction with the body Ability and the ability to provide cancer treatment. As we must consider: are patients enough to relieve or survive, or do they really want them to live again and fully recover? CAR-T cell therapy has shown effectiveness, but it is one An expensive treatment. Dr. Magialz and his team hope that these findings about improving the quality of life support the value of this treatment. “Every day there are news reports about soaring medical costs. Is it worth it? What is the value of clinical intervention? What we want to know is not only to extend the life of patients, but also to extend these times. It is meaningful to the patient. "